| Pharmaceutical Information |
| Drug Name |
Obiltoxaximab |
| Drug ID |
BADD_D01593 |
| Description |
Obiltoxaximab, an affinity-enhanced monoclonal antibody (Mab), is used for prevention and treatment of infection and death caused by anthrax toxin. Obiltoxaximab is a chimeric IgG1 kappa monoclonal antibody (mAb) that binds the PA component of B. anthracis toxin. It has an approximate molecular weight of 148 kDa. |
| Indications and Usage |
Investigated for use/treatment in anthrax exposure, bacterial infection, crohn's disease, and graft versus host disease. |
| Marketing Status |
approved |
| ATC Code |
J06BC04 |
| DrugBank ID |
DB05336
|
| KEGG ID |
D10776
|
| MeSH ID |
C000611266
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
69604-204; 67643-0018 |
| UNII |
29Z5DNL48C
|
| Synonyms |
obiltoxaximab | ETI-204 | Anthim |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
1351337-07-9 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
| ADR Term |
ADReCS ID |
ADR Frequency (FAERS)
|
ADR Severity Grade (FAERS)
|
ADR Severity Grade (CTCAE)
|
| Oropharyngeal pain | 22.12.03.016; 07.05.05.004 | - | - | |
|
|
|
